MONALISA: A Privacy-Preserving Infrastructure Supporting Liquid Biopsies to Monitor Relapsed Neuroblastoma
The survival rate for high-risk neuroblastoma remains below 50%. Current monitoring methods are costly, invasive, and stressful for patients. MONALISA will evaluate liquid biopsies as a minimally invasive alternative, to enable frequent sampling and consequently early detection of genetic tumour markers. MONALISA leverages an advanced privacy-preserving data management infrastructure, including the SIOPEN BIOPORTAL, the EUPID Services, and patient reported outcome measures, providing a model for other paediatric cancers.
Authors
- Emanuel Sandner
- Bernhard Jammerbund
- Mandy Melissa Jane Wittens (ORCID: https://orcid.org/0000-0001-5253-3106)
- Godelieve A.M. Tytgat (ORCID: https://orcid.org/0000-0003-4452-0748)
- Dieter Hayn (ORCID: https://orcid.org/0000-0003-1822-9033)
- Sabine Taschner‐Mandl (ORCID: https://orcid.org/0000-0002-1439-5301)
- Gudrun Schleiermacher (ORCID: https://orcid.org/0000-0002-0133-5879)
- Jan Köster (ORCID: https://orcid.org/0000-0002-0890-7585)
- E. Sarper Okuyan
Institutions
- AIT Austrian Institute of Technology GmbH (AT)
- Vrije Universiteit Brussel (BE)
- St Anna Children's Hospital (AT)
- Princess Máxima Center (NL)
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- St. Anna Children's Cancer Research Institute
- Institut Curie (FR)
- University of Amsterdam (NL)
Publication Details
- Journal
- Studies in health technology and informatics
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3233/shti250462
- Citations
- 1
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.84
Funders
- European Commission